* XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. * Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is XELJANZ 5 mg once daily.
Psoriatic Arthritis (in combination with nonbiologic DMARDs)
* XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. * Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is XELJANZ 5 mg once daily.
Ankylosing Spondylitis
* XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. * Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is XELJANZ 5 mg once daily.
Ulcerative Colitis
* Induction: XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily for 8 weeks; evaluate patients and transition to maintenance therapy depending on therapeutic response. If needed, continue XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily for a maximum of 16 weeks. Discontinue XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily after 16 weeks if adequate therapeutic response is not achieved. * Maintenance: XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. For patients with loss of response during maintenance treatment, XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily may be considered and limited to the shortest duration, with careful consideration of the benefits and risks for the individual patient. Use the lowest effective dose needed to maintain response. * Dosage adjustment is needed in patients with moderate and severe renal impairment or moderate hepatic impairment: see full prescribing information.
* XELJANZ/XELJANZ Oral Solution 5 mg twice daily or weight-based equivalent twice daily. * Dosage adjustment is needed in patients with moderate and severe renal impairment or moderate hepatic impairment: see full prescribing information.
Dosage Adjustment
* See the full prescribing information for dosage adjustments by indication for patients receiving CYP2C19 and/or CYP3A4 inhibitors; in patients with moderate or severe renal impairment or moderate hepatic impairment; and patients with lymphopenia, neutropenia, or anemia. * Use of XELJANZ/XELJANZ XR/XELJANZ Oral Solution in patients with severe hepatic impairment is not recommended in any patient population.
drug label
Xeljanz prescribing information
Need to report a Xeljanz issue?
ONLINE FORMReport adverse event
Learn More
You can report a Xeljanz adverse event on MedWatch, the FDA's medical product safety reporting program for health professionals, patients and consumers.
people also ask
Xeljanz FAQs
How is the dosage of Xeljanz?Xeljanz is available in 4 dosages, including 10 mg Tab, 11 mg 24 HR XR Tab, 22 mg 24 HR XR Tab and 5 mg Tab
What does Xeljanz treat?Xeljanz treats Rheumatoid Arthritis
What is Xeljanz made of?Xeljanz contains tofacitinib which is a Janus Kinase Inhibitor
How Is Xeljanz Administered?Xeljanz is administered as a Oral Pill
What Are The Xeljanz Mechanism Of Action?Xeljanz mechanism of action is Janus Kinase Inhibitors
FAQ Data Source
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available
Can't find what you're looking for?
Our trained staff can help you:
Please note:
Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.